Company Overview of Alba Therapeutics Corporation
Alba Therapeutics Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products to treat autoimmune and inflammatory diseases. It offers a technology platform based on modifying disease state epithelial permeability using compounds which impact the regulation of tight junctions in cell barriers throughout the body with applications in celiac disease, Crohn's disease, asthma/COPD, and acute lung injury. The company also provides solutions for various therapeutic areas, such as immune-based disorders, gastrointestinal diseases, metabolic diseases, pulmonary diseases, renal disease states, celiac diseases, inflammatory bowel di...
650 South Exeter Street
Baltimore, MD 21202
Founded in 2004
Key Executives for Alba Therapeutics Corporation
Compensation as of Fiscal Year 2014.
Alba Therapeutics Corporation Key Developments
Alba Therapeutics Corporation Announces Positive Results of Phase IIb Trial in Celiac Disease
Feb 11 14
Alba Therapeutics Corporation announced the positive results of their Phase IIb trial evaluating its investigational product, larazotide acetate, a tight junction regulator, intended for the treatment of patients with celiac disease (CeD). The study met its primary endpoint and, based on these results, Alba has initiated planning for Phase III clinical trials for the definitive assessment of the oral peptide's efficacy and safety. The final data will be submitted for publication in the near future. The double-blind, placebo-controlled study evaluated the efficacy and safety of larazotide acetate in the treatment of 342 patients with CeD who had persistent symptoms despite being on a gluten-free diet. This is the seventh study in a broad clinical trial program for larazotide acetate that, to date, has included 828 patients with CeD. Larazotide acetate has been granted 'Fast Track' designation from the FDA.
Alba Therapeutics Corporation Appoints Wendy Perrow as Chief Executive Officer
Nov 5 13
Alba Therapeutics Corporation announced the appointment of Wendy Perrow as its Chief Executive Officer (CEO). Her responsibilities include managing the company's business, clinical, financial, licensing, and corporate development efforts. Ms. Perrow previously served as President and COO and she has been a member of Alba's executive management team since 2008. Prior to joining Alba, Ms. Perrow held senior executive marketing positions with private and public pharmaceutical companies.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries